Ranbaxy drugs blocked, what next?
The axe has finally fallen on Ranbaxy as the US pharma regulator, USFDA, on Wednesday carried out its longstanding threat by blocking the sale of more than 30 generic medicines made at two factories of the Indian company. The FDA’s order applies to supplies from Ranbaxy’s plants in Ponta Sahib and Dewas. The US, contributing 25% to its revenues, is the single most important market for Ranbaxy.
